The HCFC1R1 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-mediated gene disruption model designed to eliminate functional expression of the HCFC1R1 (WDR82) gene. This polyclonal knockout population provides a heterogeneous pool of edited HeLa cells with targeted disruption of the HCFC1R1 locus, enabling loss-of-function studies without the need for clonal isolation. This product is an invaluable tool for investigating the role of HCFC1R1 within the SETD1/COMPASS methyltransferase complexes and its impact on histone H3K4 trimethylation-dependent transcriptional programs.
The host cell line, HeLa, is a well-established human cervical epithelial carcinoma line derived from a cervical adenocarcinoma in 1951. HeLa cells are HPV18-positive, aneuploid, and exhibit high proliferative capacity, making them a widely utilized model system in cancer biology, virology, and toxicology. Their robust growth and ease of manipulation support high-throughput genetic perturbation studies, including CRISPR/Cas9-mediated knockout experiments. This cellular background provides a physiologically relevant context for studying the molecular mechanisms underlying oncogenic transformation and tumor cell proliferation.
HCFC1R1 (WDR82) is a core subunit of the SETD1A/B methyltransferase complexes that catalyze histone H3K4 trimethylation at gene promoters. It acts as a scaffold linking the catalytic SETD1A/B enzymes to the core COMPASS-like subcomplex (WDR5, RBBP5, ASH2L, DPY30) and interacts with the coactivator HCFC1. This recruitment promotes transcriptional activation of cell cycle and proliferation genes. Upstream signals, possibly including E2F transcription factors, converge on HCFC1R1 to regulate gene expression programs essential for cell division.
Given the HeLa cell line??s derivation from a cervical carcinoma and its aneuploid, rapidly dividing nature, knockout of HCFC1R1 provides a powerful system to dissect epigenetic regulation of oncogenic transcriptional networks. Loss of HCFC1R1 is expected to perturb H3K4me3 deposition at target promoters, leading to altered expression of proliferation-associated genes and potential cell cycle defects. This model enables researchers to examine how SETD1/COMPASS complexes contribute to the malignant phenotype of epithelial cancers and to evaluate HCFC1R1 as a candidate therapeutic target in tumors dependent on H3K4 methylation.
Researchers can employ this polyclonal knockout model in a variety of experimental approaches, including chromatin immunoprecipitation followed by quantitative PCR (ChIP-qPCR) to assess H3K4me3 levels at specific promoters, RNA sequencing to profile global transcriptional changes, and functional assays such as proliferation and cell cycle analyses. It is ideally suited for studies aimed at validating HCFC1R1 as a drug target in leukemia and solid tumors, investigating SETD1/COMPASS complex assembly and dynamics, and exploring transcriptional control mechanisms in cancer epigenetics. For further technical details or to discuss customized applications, please contact Ascent Research.
